163 related articles for article (PubMed ID: 15798770)
21. Modulation of topoisomerase IIalpha expression by a DNA sequence-specific polyamide.
Hochhauser D; Kotecha M; O'hare C; Morris PJ; Hartley JM; Taherbhai Z; Harris D; Forni C; Mantovani R; Lee M; Hartley JA
Mol Cancer Ther; 2007 Jan; 6(1):346-54. PubMed ID: 17237293
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
Satterwhite DJ; White RL; Matsunami N; Neufeld KL
Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401
[TBL] [Abstract][Full Text] [Related]
23. Decreased topoisomerase IIα expression and altered histone and regulatory factors of topoisomerase IIα promoter in patients with chronic benzene poisoning.
Yu K; Shi YF; Yang KY; Zhuang Y; Zhu RH; Xu X; Cai G
Toxicol Lett; 2011 Jun; 203(2):111-7. PubMed ID: 21382456
[TBL] [Abstract][Full Text] [Related]
24. Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells.
Ando T; Nishimura M; Oka Y
Leukemia; 2000 Nov; 14(11):1915-20. PubMed ID: 11069027
[TBL] [Abstract][Full Text] [Related]
25. hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase II
Kania EE; Carvajal-Moreno J; Hernandez VA; English A; Papa JL; Shkolnikov N; Ozer HG; Yilmaz AS; Yalowich JC; Elton TS
Mol Pharmacol; 2020 Mar; 97(3):159-170. PubMed ID: 31836624
[TBL] [Abstract][Full Text] [Related]
26. Topoisomerase II-mediated alterations of K562 drug resistant sublines.
Zhou R; Wang Y; Gruber A; Larsson R; Castaños-Vèlez E; Liliemark E
Med Oncol; 1999 Sep; 16(3):191-8. PubMed ID: 10523799
[TBL] [Abstract][Full Text] [Related]
27. In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.
Taki T; Ohnishi T; Arita N; Hiraga S; Hayakawa T
J Neurooncol; 1998 Jan; 36(1):41-53. PubMed ID: 9525824
[TBL] [Abstract][Full Text] [Related]
28. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
Oloumi A; MacPhail SH; Johnston PJ; Banáth JP; Olive PL
Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
[TBL] [Abstract][Full Text] [Related]
29. Altered expression of DNA-topoisomerase IIalpha is associated with increased rate of spontaneous polyploidization in etoposide resistant K562 cells.
Melixetian MB; Beryozkina EV; Pavlenko MA; Grinchuk TM
Leuk Res; 2000 Oct; 24(10):831-7. PubMed ID: 10996201
[TBL] [Abstract][Full Text] [Related]
30. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
31. Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Jul; 92(7):799-805. PubMed ID: 11473732
[TBL] [Abstract][Full Text] [Related]
32. Establishment of a human leukemia subline resistant to the growth-inhibitory effect of 12-O-tetradecanoylphorbol 13-acetate (TPA) and showing non-P-glycoprotein-mediated multi-drug resistance.
Takeda Y; Nishio K; Sugimoto Y; Kasahara K; Kubo S; Fujiwara Y; Niitani H; Saijo N
Int J Cancer; 1991 Jul; 48(6):931-7. PubMed ID: 1677641
[TBL] [Abstract][Full Text] [Related]
33. Genome-wide DNA methylation profiling of CpG islands in a morpholino anthracycline derivative-resistant leukemia cell line: p38
Asano T; Narazaki H; Fujita A
Pharmacol Res Perspect; 2017 Feb; 5(1):e00285. PubMed ID: 28596837
[TBL] [Abstract][Full Text] [Related]
34. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
[TBL] [Abstract][Full Text] [Related]
35. The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells.
Engel R; Valkov NI; Gump JL; Hazlehurst L; Dalton WS; Sullivan DM
Exp Cell Res; 2004 May; 295(2):421-31. PubMed ID: 15093741
[TBL] [Abstract][Full Text] [Related]
36. Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide.
Grabowski DR; Holmes KA; Aoyama M; Ye Y; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Mol Pharmacol; 1999 Dec; 56(6):1340-5. PubMed ID: 10570063
[TBL] [Abstract][Full Text] [Related]
37. Selection of non-P-glycoprotein mediated high-level etoposide resistant cell lines by adriamycin with P-gp inhibitors.
Ades S; Maxfield LF; Gould CJ; Jones GK; Levy SB
Int J Oncol; 2006 Mar; 28(3):747-53. PubMed ID: 16465381
[TBL] [Abstract][Full Text] [Related]
38. Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha.
Herzog CE; Holmes KA; Tuschong LM; Ganapathi R; Zwelling LA
Cancer Res; 1998 Dec; 58(23):5298-300. PubMed ID: 9850052
[TBL] [Abstract][Full Text] [Related]
39. Characterization of human NSCLC cell line with innate etoposide-resistance mediated by cytoplasmic localization of topoisomerase II alpha.
de Lucio B; Manuel V; Barrera-Rodríguez R
Cancer Sci; 2005 Nov; 96(11):774-83. PubMed ID: 16271071
[TBL] [Abstract][Full Text] [Related]
40. Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
Uggla B; Tina E; Nahi H; Paul C; Höglund M; Sirsjö A; Tidefelt U
Int J Oncol; 2007 Jul; 31(1):153-60. PubMed ID: 17549416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
